Literature DB >> 2091335

Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults.

W M Watkins1, E K Mberu, C G Nevill, S A Ward, A M Breckenridge, D K Koech.   

Abstract

Extensive metabolizers (EM) and poor metabolizers (PM) of the malaria chemoprophylactic drug proguanil have been identified by measuring the proguanil/cycloguanil ratio in urine following a single dose of the pro-drug. The pharmacokinetic characteristics of proguanil were similar in 8 EM and 8 PM subjects, but there were significant differences between the 2 groups with respect to cycloguanil pharmacokinetics. In none of the PM subjects could cycloguanil be detected in whole blood samples at any time after proguanil dosage. Plasma cycloguanil was measureable in only 2 of 8 PM subjects, despite an analytical sensitivity in the high-performance liquid chromatographic assay of 1 ng/ml cycloguanil. A comparatively high proportion of Black Kenyan adults appear to metabolize proguanil poorly, possibly because they lack the specific mixed function oxidase which will accept proguanil as substrate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2091335     DOI: 10.1016/0035-9203(90)90010-c

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  14 in total

Review 1.  The evolution of drug-resistant malaria: the role of drug elimination half-life.

Authors:  Ian M Hastings; William M Watkins; Nicholas J White
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

4.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

5.  Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.

Authors:  J Wangboonskul; N J White; F Nosten; F ter Kuile; R R Moody; R B Taylor
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.

Authors:  M D Edstein; G D Shanks; P Teja-Isavadharm; K H Rieckmann; H K Webster
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

7.  The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.

Authors:  J D Wright; N A Helsby; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  The multiple dose pharmacokinetics of proguanil.

Authors:  N A Helsby; G Edwards; A M Breckenridge; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

9.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

10.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.